



## **TO THE NATIONAL SECURITIES MARKET COMMISSION**

Madrid, 12 April, 2021

### **PRICE-SENSITIVE INFORMATION**

Complying with the information duties set out in article 226 of the Revised Text of the Securities Market Act, Laboratorios Farmacéuticos ROVI, S.A. (ROVI) issues and publishes the press release attached hereto concerning the extension of the collaboration that currently exists between ROVI and Moderna for the manufacture of Moderna's COVID-19 vaccine outside the United States. ROVI will carry out not only the fill-finish of the vaccine but will also take part in the manufacture of the active substance. The press release will be distributed today and may be accessed through the Company's website.

Juan López-Belmonte Encina  
Chief Executive Officer and General Manager  
Laboratorios Farmacéuticos ROVI, S.A.



## **ROVI participates in the manufacture of the active substance of Moderna's COVID-19 vaccine**

- **Investment in a new production line at ROVI's Granada facility**
- **Greater vertical integration of the vaccine production process**

**Madrid, Spain – 12 April, 2021** – Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties, today announced that they will strengthen their collaboration for the manufacture of the active substance of the COVID-19 Vaccine Moderna. To this end, further industrial investment will be made in the ROVI Group's facility in Granada (Spain).

This investment consists of the installation of a new line supporting production phases of the active substance of the mRNA vaccine, which are prior and additional to the compounding and fill-finish of the vaccine. This line will have a production capacity equivalent to more than 100 million doses per year and is expected to begin to supply markets outside the United States in the third quarter of 2021.

With this addition, ROVI will extend the activities it performs in the manufacturing process of the COVID-19 Vaccine Moderna: it will take part in the manufacture of the active substance, as well as the compounding, filling and final packaging before the vaccine is distributed for administration to patients.

Juan López-Belmonte Encina, ROVI's Chief Executive Officer, said, "*We are delighted at our collaboration with Moderna, whose vaccine against COVID-19 is one of the best-positioned in the race to solve this health crisis. We are hugely excited that ROVI is taking a further step forward and taking part in the manufacture of the vaccine's active*

*substance, since greater integration in the production process will allow us to support Moderna in its large-scale distribution more broadly. We are thrilled at the chance to increase our contribution to solving this pandemic that is affecting everyone. Our proven experience and capacities as a contract manufacturer of injectables with high technological value has enabled us to strengthen our present agreement with Moderna and this will help to reinforce our manufacturing area, probably providing us with a significant growth opportunity in this area. I would also like to thank the Ministry of Health and the Spanish Medicines Agency for making themselves available to us and providing their support during this entire process. This has been of vital importance.*

### **About ROVI**

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, already marketed in 58 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its enoxaparin biosimilar, developed in-house, in Europe. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit [www.rovi.es](http://www.rovi.es).

### **ROVI's Forward-looking statements**

This news release contains forward-looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance, or achievements of ROVI or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward looking statements. These risks, uncertainties, and other factors include, among others: the fact that no commercial product utilising mRNA technology has been approved for use before; the fact that the manufacturing infrastructure required to manufacture mRNA-1273 is still being developed and implemented; potential adverse impacts due to the global COVID-19 pandemic, such as delays in regulatory review, manufacturing and

supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy. The statements in this press release represent ROVI's expectations and beliefs as of the date of this press release. ROVI anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while ROVI may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ROVI's expectations or beliefs as of any date subsequent to the date of this press release.

## **ROVI Contacts**

### **Investors:**

Marta Campos Martínez

+34 607 539 780

[mcampos@rovi.es](mailto:mcampos@rovi.es)

Antonio Marquina Ospina

+34 674 315 715

[amarquina@rovi.es](mailto:amarquina@rovi.es)

### **Media:**

Beatriz García Suárez

+34 662 570 818

[bgarciasuarez@rovi.es](mailto:bgarciasuarez@rovi.es)